FOLH1 and pachyonychia congenita: One such target is neurotensin receptor1 (NTSR1), which exhibits high or moderate expression in 92% of PC tumors, including all PSMA-negative tissues, suggesting a potential complementary role in targeted imaging or/and therapy [60].